Lexeo Therapeutics (NASDAQ:LXEO) Upgraded by Raymond James Financial to Strong-Buy Rating

Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by equities researchers at Raymond James Financial to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities analysts have also recently commented on LXEO. Cantor Fitzgerald initiated coverage on Lexeo Therapeutics in a report on Monday, December 1st. They set an “overweight” rating and a $19.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. Leerink Partners lifted their target price on Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. HC Wainwright reissued a “buy” rating on shares of Lexeo Therapeutics in a report on Monday, November 3rd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Lexeo Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $19.33.

Lexeo Therapeutics Trading Up 3.9%

NASDAQ:LXEO opened at $10.35 on Wednesday. The stock has a market capitalization of $755.45 million, a PE ratio of -3.83 and a beta of 1.76. Lexeo Therapeutics has a 1-year low of $1.45 and a 1-year high of $10.79. The firm has a fifty day simple moving average of $9.25 and a 200 day simple moving average of $6.39.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.15. On average, equities analysts predict that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 13,133 shares of the company’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $117,409.02. Following the transaction, the chief executive officer directly owned 242,118 shares of the company’s stock, valued at $2,164,534.92. This represents a 5.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Tai Sandi See sold 3,888 shares of the stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $34,758.72. Following the transaction, the insider owned 65,862 shares in the company, valued at $588,806.28. The trade was a 5.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 24,646 shares of company stock worth $221,037. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors have recently modified their holdings of the business. Nuveen LLC acquired a new position in shares of Lexeo Therapeutics in the first quarter valued at about $125,000. Affinity Asset Advisors LLC bought a new stake in Lexeo Therapeutics in the 1st quarter valued at about $5,139,000. AQR Capital Management LLC grew its position in shares of Lexeo Therapeutics by 370.0% during the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after purchasing an additional 39,627 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Lexeo Therapeutics by 654.8% during the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after purchasing an additional 929,538 shares during the period. Finally, Acadian Asset Management LLC bought a new position in shares of Lexeo Therapeutics during the first quarter worth approximately $85,000. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.